Maintenance treatment with interferon alpha-2b in multiple myeloma: A prospective randomized study from PETHEMA (Program for the Study and Treatment of Hematological Malignancies, Spanish Society of Hematology)

Leukemia

Volumn 12, Issue 7, 1998, Pages 1144-1148

  Blade J ^a   San Miguel, J F ^a   Escudero, M L ^a   Fontanillas, M ^a   Besalduch, J ^a   Gardella, S ^a   Arias, J ^a   Garcia Conde J ^a   Carnero, M ^a   Marti, J M ^a   Rozman, C ^a   Estape J ^a   Montserrat, E ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

Interferon; Maintenance treatment; Multiple myeloma

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; MELPHALAN; PREDNISONE; RECOMBINANT ALPHA2B INTERFERON; VINCRISTINE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFICACY; DRUG TOXICITY; FATIGUE; FEMALE; FEVER; GRANULOCYTOPENIA; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; REMISSION; SPAIN; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 17344366696     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401039     Document Type: Article

References (29)

1. Alexanian R, Haut A, Khan A, Lane M, McKelvey EM, Migliore PJ, Stuckey Jr J, Wilson HE. Treatment for multiple myeloma with different melphalan dose regimens. J Am Med Assoc 1969; 208: 1680-1685.
2. Bergsagel DE. Chemotherapy of myeloma. In: Malpas JS, Bergsagel DE, Kyle RA, Anderson K (eds). Myeloma Biology and Management. Oxford University Press: Oxford, 1998, pp 269-302.
3. Blade J, San Miguel JF, Alcald A, Maldonado J, Sanz MA, Garcia Conde J, Moro MJ, Alonso C, Besalduch J, Zubizarreta A, Besses C, González-Brito G, Hernández-Martin J, Fernández-Calvo J, Rubio D, Ortega F, Jiménez R, Colominas P, Faura MV, Font LL, Tortosa J, Domingo A, Fontanillas M, Rozman C, Estapé J. Alternating combination VCMP/VBAP chemotherapy versus melphalan/ prednisone in the treatment of ultiple myeloma: a randomized multicentric study of 487 patients. J Clin Oncol 1993; 11: 1165-1171.
4. Belch A, Shelley W, Bergsagel D, Wilson K, Klimo P, White D, Willan A. A randomized trial of maintenance versus no maintenance melphalan and prednisone in responding multiple myeloma patients. Br J Cancer 1988; 57: 94-99.
5. Mellstedt H, Ahre A, Björkholm M, Holm G, Johansson B, Strander H. Interferon therapy in multiple myeloma. Lancet 1979; i: 245-247.
6. Brenning G, Ahre A, Nilsson K. Correlation between in vitro and in vivo sensitivity of human leukocyte interferon in patients with multiple myeloma. Scand J Haematol 1985; 35: 543-549.
7. Peest D, Bladé J, Harousseau JL, Klein B, Österborg A, San Miguel JF. Cytokine therapy in multiple myeloma. Br J Haematol 1996; 94: 425-132.
8. Drayson MT, Dunn JA, Olujohungbe AB, MacLennan ICM. Alpha2b-interferon treatment used in plateau phase of multiple myeloma increases relapse-free survival but not overall survival. Blood 1996; 88: (Suppl. 1): 586a (Abstr.).
9. Chronic Leukemia-Myeloma Task Force, National Cancer Institute. Proposed guidelines for protocol studies. II. Plasma cell myeloma. Cancer Chemother Rep 1973; 4: 145-158.
10. Durie BGM, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975; 36: 842-854.
11. Bladé J, San Miguel JF, Escudero ML, Maldonado J, Brunet S, Gardella S, Alcalá A, Carnero M, Carbonell F, Garcia-Conde J, Besalduch J, Marti JM, Ribera JM, Atucha J, Fernándndez-Calvo J, Font LI, Moro MJ, Fontanillas M, Estapé J, Montserrat E. VCMP/VBAP at standard doses vs VCMP/VBAP at higher doses of cyclophosphamide and doxorubicin as initial treatment of multiple myeloma. Blood 1996; 88 (Suppl. 1): 587a (Abstr.).
12. Kaplan GL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
13. 2/E in the log-rank test for survival data or tumour incidence data. Biometrics 1973; 29: 759-784.
14. World Health Organization. Handbook for Reporting Results of Cancer Treatment. WHO Offset Publications, No. 48: Geneva, 1979.
15. Durie BGM, Russell DH, Salmon SE. Reappraisal of plateau phase in myeloma. Lancet 1980; ii: 65-67.
16. Bergsagel DE, Bailey AJ, Langley GR, McDonald RN, White DF, Miller AB. The chemotherapy of plasma cell myeloma and the incidence of acute leukemia. New Engl J Med 1979; 301: 743-748.
17. Joshua DE, Brown RD, Gibson J. Multiple myeloma: why does the disease escape from plateau phase? Br J Haematol 1994; 88: 667-671.
18. Kyle RA. Monoclonal gammopathy of undetermined significance. Natural history in 241 cases. Am J Med 1978; 64: 814-826.
19. Kyle RA, Greipp PR. Smoldering multiple myeloma. New Engl J Med 1980; 302: 1347-1349.
20. Mandelli F, Avvisati G, Amadori S, Boccadoro M, Gernone A, Lauta VM, Marmont F, Petrucci MT, Tribaldo M, Vegna ML, Dammacco F, Pileri A. Maintenance treatment with recombinant Interferon alfa-2b in patients with multiple myeloma responding to conventional induction chemotherapy. New Engl J Med 1990; 322: 1430-1434.
21. Westin J, Rodjer S, Turesson I, Cortelezzi A, Hjorth M, Zador G. Interferon alpha-2b versus no maintenance during the plateau phase in multiple myeloma: a randomized study. Br J Haematol 1995; 89: 561-568.
22. Ludwig H, Cohen AM, Polliak A, Huber H, Nachbaur D, Senn HJ, Morant R, Eckhardt S, Günczler P, Seewann HL, Schüller J, Rhyner K, Cavalli F, Fritz E. Interferon-alpha for induction and maintenance in multiple myeloma: results of two multicenter randomized trials and summary of other studies. Ann Oncol 1995; 6: 467-476.
23. Browman CP, Bergsagel DE, Sicheri D, O'Reilly S, Wilson KS, Rubin S, Belch A, Shustik C, Barr R, Walker I, James K, Zee B, Johnston D. Randomized trial of interferon maintenance in multiple myeloma: a study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1995; 13: 2354-2360.
24. Salmon SE, Crowley J, Grogan TM, Finley P, Pugh HP, Barlogie B. Combination chemotherapy, glucocorticoids, and interferon alpha in the treatment of multiple myeloma. A Southwest Oncology Group Study. J Clin Oncol 1994; 12: 2405-2414.
25. Peest D, Deicher H, Coldeway R, Leo R, Bartl R, Bartels H, Braun HJ, Fett W, Fischer JT, Go
26. Capnist G, Vespignani M, Spriano M, Damasio E, Cavriotto L, Rizzoli V, Contu A, Olmeo N, Tedeschi L, Fabris P, Chisesi T. Impact of interferon induction chemotherapy and maintenance treatment for multiple myeloma. Acta Oncologica 1994; 33: 527-529.
27. Cunningham D, Raje N, Powles R, Malpas JS, Singhal S, Metha J, Viner C, Treleavan J. Maintenance therapy for remission in myeloma with Intron A following high-dose melphalan and either an autologous bone marrow transplantation or peripheral stem-cell rescue. Stem Cells 1995; 13: 114-117.
28. Palumbo A, Boccadoro M, Garino LA, Gallone G, Frieri R, Pileri A. Multiple myeloma: intensified maintenance therapy with recombinant interferon alpha-2b plus glucocorticoids. Eur J Hemato/1992; 49: 93-97.
29. Salmon SE, Crowley JJ. Alpha interferon plus alternate day prednisone improves remission duration in multiple myeloma compared to interferon alone. Proc Am Soc Clin Oncol 1997; 16: 13a.